Pancreatic Adenocarcinoma, Version 2.2012

Featured Updates to the NCCN Guidelines

Restricted access

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.

  • 1

    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:1029.

  • 2

    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277300.

  • 3

    Arnold LD, Patel AV, Yan Y. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Cancer Epidemiol Biomarkers Prev 2009;18:23972405.

    • Search Google Scholar
    • Export Citation
  • 4

    StatBite. U.S. pancreatic cancer rates. J Natl Cancer Inst 2010;102:1822.

  • 5

    Bilimoria KY, Talamonti MS, Sener SF. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 2008;207:510519.

    • Search Google Scholar
    • Export Citation
  • 6

    Winter JM, Cameron JL, Campbell KA. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:11991210.

    • Search Google Scholar
    • Export Citation
  • 7

    Zervos EE, Rosemurgy AS, Al-Saif O, Durkin AJ. Surgical management of early-stage pancreatic cancer. Cancer Control 2004;11:2331.

  • 8

    Callery MP, Chang KJ, Fishman EK. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009;16:17271733.

    • Search Google Scholar
    • Export Citation
  • 9

    Wong JC, Lu DSK. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol 2008;6:13011308.

  • 10

    Fuhrman GM, Charnsangavej C, Abbruzzese JL. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994;167:104111.

    • Search Google Scholar
    • Export Citation
  • 11

    Horton KM, Fishman EK. Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am 2002;40:12631272.

  • 12

    House MG, Yeo CJ, Cameron JL. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg 2004;8:280288.

    • Search Google Scholar
    • Export Citation
  • 13

    Klauss M, Schobinger M, Wolf I. Value of three-dimensional reconstructions in pancreatic carcinoma using multidetector CT: initial results. World J Gastroenterol 2009;15:58275832.

    • Search Google Scholar
    • Export Citation
  • 14

    McNulty NJ, Francis IR, Platt JF. Multi-detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and pancreatic adenocarcinoma. Radiology 2001;220:97102.

    • Search Google Scholar
    • Export Citation
  • 15

    Gabata T, Matsui O, Kadoya M. Small pancreatic adenocarcinomas: efficacy of MR imaging with fat suppression and gadolinium enhancement. Radiology 1994;193:683688.

    • Search Google Scholar
    • Export Citation
  • 16

    Ichikawa T, Haradome H, Hachiya J. Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imaging. Radiology 1997;202:655662.

    • Search Google Scholar
    • Export Citation
  • 17

    Kauhanen SP, Komar G, Seppanen MP. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 2009;250:957963.

    • Search Google Scholar
    • Export Citation
  • 18

    Schima W, Fugger R, Schober E. Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT. AJR Am J Roentgenol 2002;179:717724.

    • Search Google Scholar
    • Export Citation
  • 19

    Schima W, Ba-Ssalamah A, Goetzinger P. State-of-the-art magnetic resonance imaging of pancreatic cancer. Top Magn Reson Imaging 2007;18:421429.

    • Search Google Scholar
    • Export Citation
  • 20

    Olivie D, Lepanto L, Billiard JS. Predicting resectability of pancreatic head cancer with multi-detector CT. Surgical and pathologic correlation. JOP 2007;8:753758.

    • Search Google Scholar
    • Export Citation
  • 21

    Vachiranubhap B, Kim YH, Balci NC, Semelka RC. Magnetic resonance imaging of adenocarcinoma of the pancreas. Top Magn Reson Imaging 2009;20:39.

    • Search Google Scholar
    • Export Citation
  • 22

    Walters DM, Lapar DJ, de Lange EE. Pancreas-protocol imaging at a high-volume center leads to improved preoperative staging of pancreatic ductal adenocarcinoma. Ann Surg Oncol 2011;18:27642771.

    • Search Google Scholar
    • Export Citation
  • 23

    Conroy T, Desseigne F, Ychou M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:18171825.

  • 24

    Taieb J, Lecomte T, Aparicio T. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol 2007;18:498503.

    • Search Google Scholar
    • Export Citation
  • 25

    Yoo C, Hwang JY, Kim JE. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009;101:16581663.

    • Search Google Scholar
    • Export Citation
  • 26

    Pelzer U, Schwaner I, Stieler J. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011;47:16761681.

    • Search Google Scholar
    • Export Citation
  • 27

    Xiong HQ, Varadhachary GR, Blais JC. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008;113:20462052.

    • Search Google Scholar
    • Export Citation
  • 28

    Washington K, Berlin J, Branton P. Protocol for the examination of specimens from patients with carcinoma of the exocrine pancreas. Available at: http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2011/PancreasExo_11protocol.pdf. Accessed March 20. 2012.

    • Search Google Scholar
    • Export Citation
  • 29

    Gumbs AA, Rodriguez Rivera AM, Milone L, Hoffman JP. Laparoscopic pancreatoduodenectomy: a review of 285 published cases. Ann Surg Oncol 2011;18:13351341.

    • Search Google Scholar
    • Export Citation
  • 30

    Nakeeb A, Lillemoe KD, Grosfeld JL. Surgical techniques for pancreatic cancer. Minerva Chir 2004;59:151163.

  • 31

    Yeo TP, Hruban RH, Leach SD. Pancreatic cancer. Curr Probl Cancer 2002;26:176275.

  • 32

    Wayne JD, Abdalla EK, Wolff RA. Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist 2002;7:3445.

    • Search Google Scholar
    • Export Citation
  • 33

    Baque P, Iannelli A, Delotte J. Division of the right posterior attachments of the head of the pancreas with a linear stapler during pancreaticoduodenectomy: vascular and oncological considerations based on an anatomical cadaver-based study. Surg Radiol Anat 2009;31:1317.

    • Search Google Scholar
    • Export Citation
  • 34

    Evans DB, Pisters PW. Novel applications of endo GIA linear staplers during pancreaticoduodenectomy and total pancreatectomy. Am J Surg 2003;185:606607.

    • Search Google Scholar
    • Export Citation
  • 35

    Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg 1996;224:342347; discussion 347–349.

    • Search Google Scholar
    • Export Citation
  • 36

    Riediger H, Makowiec F, Fischer E. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg 2006;10:11061115.

    • Search Google Scholar
    • Export Citation
  • 37

    Tseng JF, Raut CP, Lee JE. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8:935949.

    • Search Google Scholar
    • Export Citation
  • 38

    Stitzenberg KB, Watson JC, Roberts A. Survival after pancreatectomy with major arterial resection and reconstruction. Ann Surg Oncol 2008;15:13991406.

    • Search Google Scholar
    • Export Citation
  • 39

    Christein JD, Kendrick ML, Iqbal CW. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg 2005;9:922927.

    • Search Google Scholar
    • Export Citation
  • 40

    Shoup M, Conlon KC, Klimstra D, Brennan MF. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? J Gastrointest Surg 2003;7:946952; discussion 952.

    • Search Google Scholar
    • Export Citation
  • 41

    Strasberg SM, Linehan DC, Hawkins WG. Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. J Am Coll Surg 2007;204:244249.

    • Search Google Scholar
    • Export Citation
  • 42

    Verbeke CS. Resection margins and R1 rates in pancreatic cancer—are we there yet? Histopathology 2008;52:787796.

  • 43

    Gebhardt C, Meyer W, Reichel M, Wunsch PH. Prognostic factors in the operative treatment of ductal pancreatic carcinoma. Langenbecks Arch Surg 2000;385:1420.

    • Search Google Scholar
    • Export Citation
  • 44

    Mitsunaga S, Hasebe T, Iwasaki M. Important prognostic histological parameters for patients with invasive ductal carcinoma of the pancreas. Cancer Sci 2005;96:858865.

    • Search Google Scholar
    • Export Citation
  • 45

    Japan Pancreatic Society. Classification of Pancreatic Carcinoma, 2nd ed. Tokyo, Japan: Kanehara; 2003.

  • 46

    Campbell F, Foulis AK, Verbeke CC. Dataset for the Histopathological Reporting of Carcinomas of the Pancreas, Ampulla of Vater and Common Bile Duct. London, England: The Royal College of Pathologists; 2010.

    • Search Google Scholar
    • Export Citation
  • 47

    Hruban RH, Pitman MB, Klimstra DS. Tumors of the Pancreas: AFIP Atlas of Tumor Pathology, 4th Series, Fascicle 6. Washington, DC: Armed Forces Institutes of Pathology; 2007.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 629 405 38
PDF Downloads 86 60 4
EPUB Downloads 0 0 0